Trial Profile
A Single Centre, Pilot Trial of YF476 in Patients With Chronic Atrophic Gastritis, Hypergastrinaemia and Type I Gastric Carcinoids
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Netazepide (Primary)
- Indications Gastric cancer; Gastritis; Neuroendocrine tumours
- Focus Therapeutic Use
- Sponsors Trio Medicines
- 14 May 2015 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov record.
- 03 Oct 2011 New trial record